New drug could shrink eye tumors, saving sight

NCT ID NCT06414590

Recruiting now Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated Jun 13, 2026 · Updated 26 times

Summary

This study tests a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that is too large to remove without taking the whole eye. The goal is to see if the drug can shrink the tumor by at least 20% so that less invasive surgery might be possible. Participants receive the drug before any other treatment and will have biopsies to check the effect.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Wills Eye Hospital
ACTIVE_NOT_RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED UNRESECTABLE UVEAL MELANOMA